Soleno Therapeutics, Inc. (SLNO)
After hours:
- GuruFocus.com
Insider Sell Alert: CFO James Mackaness Sells 8,081 Shares of Soleno Therapeutics Inc (SLNO)
James Mackaness, the Chief Financial Officer of Soleno Therapeutics Inc, has recently made a significant change in his holdings of the company's stock.
- GlobeNewswire
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees. The Compensation Committee, consisting of independent members of the Board of Directors of Soleno, approved the grant of non-qualified stock options to purchase 145,000 s
- GlobeNewswire
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Corporate Highlights Announced positive statistically significant top-line data from the randomized withdrawal period of Study C602, a long-t
